The Value of SUV of FDG-PET/CT in Differentiation of Myeloma and Metastasis in Patients with Malignant Skeletal Diseases of Unknown Origin

戴东,徐文贵,王琦,宋秀宇,朱磊,王健,朱研佳,朱湘
DOI: https://doi.org/10.3760/cma.j.issn.0253-2352.2009.12.008
2009-01-01
Abstract:Objective To conduct a comparison of the standardized uptake value (SUV) of positron emission tomography/computed tomography (PET/CT) in myeloma and multiple bone metastasis disease. Methods A total of 119 patients with osteolysis were analyzed. There were 40 males and 31 females, with the mean age of 61.3 years. There were myelomas in 21 patients bone metastases diease in 41 patients,confirmed by histological section. Lesions of meyloma and bone metastasis disease were calculated. Feasible cutoff values of differentiation were determined by using the receiver operating characteristic (ROC) curve based positive test. A Comparion of the SUVmax between the multiple bone metastasis disease and myeloma was performed. Restlts PET/CT identified increased FDG uptake in 315 lesions in patients with myeloma, and 684 lesions in patients with metastases. SUVmax of myelomas were lower than metastastic lesions. The value of 4.45 had been proved to be appropriate in the differentiation of myeloma and multiple bone metastasis disease, the diagnostic sensitivity and specificity was 80.4% and 72.49b respectively. The SUVmax of osteolystic metastastic lesions were significantly higher than that of osteogenic metastastic lesions and lesions of myeloma, but no difference was found between the osteogenic metastastic lesions and lesions of myeloma. Conclusion FDG-PET/CT had potential value in the differentiation of myeloma and multiple bone metastasis diseases. Low SUVmax and uncertainty of origin suggested myeloma.
What problem does this paper attempt to address?